Trump administration’s embattled FDA vaccine chief is leaving for the second time

FDA’s Top Vaccine Regulator Leaves Amid String of Controversies

The Food and Drug Administration’s vaccine chief, Dr. Vinay Prasad, will depart the agency at the end of April, marking his second exit in less than a year. FDA Commissioner Marty Makary announced the departure in an email to staff late Friday, noting that Prasad would return to his academic position at the University of California, San Francisco.

Prasad’s tenure has been marked by controversy and high-profile disputes with pharmaceutical companies. His departure comes after a series of contentious decisions that have drawn criticism from drug manufacturers, investors, patient advocacy groups, and members of Congress.

In July, Prasad was temporarily removed from his position after clashing with biotech executives and patient groups. He was reinstated less than two weeks later with support from Health Secretary Robert F. Kennedy Jr. and Commissioner Makary, highlighting the political dynamics at play within the agency.

The latest chapter in Prasad’s turbulent FDA career involves several public disputes with pharmaceutical companies developing vaccines and treatments for rare diseases. Most recently, Prasad initially rejected Moderna’s application for review of a highly anticipated mRNA-based flu vaccine. This unusual move prompted Moderna to publicly challenge the decision.

Following industry backlash, the FDA reversed course just a week later, agreeing to review the vaccine pending an additional study from Moderna. This rapid policy reversal raised questions about consistency in the agency’s decision-making process under Prasad’s leadership.

In another unprecedented clash, the FDA engaged in a public confrontation with UniQure, a small biotechnology company developing a gene therapy for Huntington’s Disease, a fatal condition affecting approximately 40,000 Americans. UniQure disclosed that the FDA had demanded a new clinical trial that would involve performing sham brain surgery on some patients, a requirement the company described as contradicting previous FDA guidance and raising ethical concerns.

In a highly unusual move, the FDA held a press conference to criticize UniQure’s therapy. A senior FDA official, speaking anonymously to reporters, described the company’s original study as “stone cold negative” and the therapy as a “failed product.” Such direct public criticism of an experimental treatment still under regulatory review represents a significant departure from the FDA’s typically measured communications approach.

Prasad’s regulatory approach has perplexed many industry observers. As a longtime academic and critic of FDA standards before joining the agency in May, his tenure has been characterized by seemingly contradictory positions. While sometimes joining Commissioner Makary in announcing initiatives to streamline FDA drug reviews, he also imposed new warnings and study requirements for certain biotechnology products and vaccines, particularly COVID-19 shots that had been frequently criticized by Secretary Kennedy, who was known for anti-vaccine activism before joining the Trump administration.

The impact of Prasad’s decisions extends beyond high-profile disputes. More than half a dozen pharmaceutical companies developing therapies for rare or difficult-to-treat conditions have received rejection letters or requirements for additional studies during his tenure. These decisions potentially add years to development timelines and millions of dollars in costs for treatments aimed at patients with limited therapeutic options.

The pattern of regulatory reversals and public disputes under Prasad’s leadership has created uncertainty in the pharmaceutical industry about the agency’s review standards and decision-making processes. His departure may signal a potential shift in the FDA’s approach to evaluating vaccines and biologics at a time when innovative technologies like mRNA and gene therapy are expanding therapeutic possibilities.

As Prasad prepares to return to academia, the FDA faces the challenge of rebuilding relationships with the industry it regulates while maintaining its scientific standards and commitment to public health.